Carbidopa

卡比多巴

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameCarbidopa
Drug Alias NameCarbidopum碳度巴卡别多巴甲基多巴肼Lodosyn +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDOPA decarboxylase inhibitors
TargetsAromatic-L-amino-acid decarboxylase
Therapy Area/IndicationsParkinson DiseasePostural Orthostatic Tachycardia SyndromeOrthostatic Intolerance
Global Approved IndicationsParkinson Disease
Approved Indications in ChinaParkinson Disease
Original Approved Country/TerritoryUnited States
Original Approved Date1977/04/25
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesAtonVanderbilt UniversityNantong Jinghua Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsParkinson DiseasePostural Orthostatic Tachycardia SyndromeOrthostatic Intolerance
Inactive IndicationsN/A

Other Information

ATC CodeN04BA03
Related LinksWikipediaDrugBankKEGG